Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Department of Dermatology, Hospital of Valais, Sierre, Switzerland.
Nat Genet. 2016 Apr;48(4):398-406. doi: 10.1038/ng.3525. Epub 2016 Mar 7.
Basal cell carcinoma (BCC) of the skin is the most common malignant neoplasm in humans. BCC is primarily driven by the Sonic Hedgehog (Hh) pathway. However, its phenotypic variation remains unexplained. Our genetic profiling of 293 BCCs found the highest mutation rate in cancer (65 mutations/Mb). Eighty-five percent of the BCCs harbored mutations in Hh pathway genes (PTCH1, 73% or SMO, 20% (P = 6.6 × 10(-8)) and SUFU, 8%) and in TP53 (61%). However, 85% of the BCCs also harbored additional driver mutations in other cancer-related genes. We observed recurrent mutations in MYCN (30%), PPP6C (15%), STK19 (10%), LATS1 (8%), ERBB2 (4%), PIK3CA (2%), and NRAS, KRAS or HRAS (2%), and loss-of-function and deleterious missense mutations were present in PTPN14 (23%), RB1 (8%) and FBXW7 (5%). Consistent with the mutational profiles, N-Myc and Hippo-YAP pathway target genes were upregulated. Functional analysis of the mutations in MYCN, PTPN14 and LATS1 suggested their potential relevance in BCC tumorigenesis.
皮肤基底细胞癌 (BCC) 是人类最常见的恶性肿瘤。BCC 主要由 Sonic Hedgehog (Hh) 通路驱动。然而,其表型变异仍未得到解释。我们对 293 例 BCC 的基因谱分析发现,癌症的突变率最高(65 个突变/Mb)。85%的 BCC 存在 Hh 通路基因(PTCH1,73%或 SMO,20%(P = 6.6×10(-8)) 和 SUFU,8%)和 TP53(61%)的突变。然而,85%的 BCC 还存在其他癌症相关基因的额外驱动突变。我们观察到 MYCN(30%)、PPP6C(15%)、STK19(10%)、LATS1(8%)、ERBB2(4%)、PIK3CA(2%)和 NRAS、KRAS 或 HRAS(2%)的复发性突变,以及 PTPN14(23%)、RB1(8%)和 FBXW7(5%)中存在功能丧失和有害错义突变。与突变谱一致,N-Myc 和 Hippo-YAP 通路靶基因上调。对 MYCN、PTPN14 和 LATS1 突变的功能分析表明,它们可能与 BCC 肿瘤发生有关。
Int J Mol Sci. 2017-11-22
Am J Clin Dermatol. 2018-4
J Invest Dermatol. 2019-1-29
Cancer Cell. 2015-3-9
Skinmed. 2017-8-1
Cancer Cell. 2015-3-9
Oncogenesis. 2025-8-26
Int J Mol Sci. 2025-7-19
J Cancer Prev. 2025-6-30
Cell Death Discov. 2025-7-3
Am J Ophthalmol Case Rep. 2025-3-5
J Invest Dermatol. 2015-12
Cell. 2015-6-18
Nat Commun. 2015-4-9
Cancer Cell. 2015-3-9
Cancer Cell. 2015-3-9
Oncotarget. 2015-3-30
Nature. 2015-2-19